Cure8 research brief
Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow fibrosis in IBD.
Researchers studying IBD fibrosis and epithelial biology; clinicians interested in mechanisms of IBD complications and future anti‑fibrotic therapies; adult patients worried about stricturing disease and surgical risk.
The work highlights inflammatory fibroblasts and epithelial‑to‑mesenchymal plasticity as interacting contributors to intestinal fibrosis rather than a single dominant pathway. Transforming growth factor‑β (TGF‑β) signaling is identified as a central driver of fibroblast activation and fibrotic changes.
The thesis reports that the JAK inhibitor upadacitinib and the anti‑fibrotic agent pirfenidone reduced expression of IL13RA2, a receptor linked to inflamed tissue and activated fibroblast states, in experimental models.
It also shows that inflammatory and fibrotic signals can induce reversible epithelial changes in human intestinal organoids that were preventable by blocking TGF‑β–related signaling.
Takeaway for patients and clinicians: the findings suggest anti‑fibrotic strategies for IBD may need to target both fibroblasts and epithelial changes; some existing drugs could inform future anti‑fibrotic approaches, but this is preclinical and exploratory.
This entry is a doctoral thesis (abstract and full text available) reporting experimental and translational research, including organoid and cell‑level studies. Findings are mechanistic and exploratory; they do not constitute clinical trial evidence that the drugs named prevent or reverse fibrosis in patients.
Pirfenidone and upadacitinib effects reported here come from laboratory models and need clinical validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
